Cargando…
A Review of the Advancements in Targeted Therapies for Breast Cancer
Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679843/ https://www.ncbi.nlm.nih.gov/pubmed/38022130 http://dx.doi.org/10.7759/cureus.47847 |
_version_ | 1785142258589237248 |
---|---|
author | Jallah, John Kessellie Dweh, Tuward J Anjankar, Ashish Palma, Ogiza |
author_facet | Jallah, John Kessellie Dweh, Tuward J Anjankar, Ashish Palma, Ogiza |
author_sort | Jallah, John Kessellie |
collection | PubMed |
description | Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have experienced a profound transformation in treating breast cancer, allowing for individualized strategies that lessen side effects and improve patient outcomes. This thorough analysis gives a rigorous investigation of current developments in breast cancer-targeted treatments. It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. It offers specialized treatment plans catered to each subtype's particular traits. The review also examines how precise genetic abnormalities like BRCA1/2 and PIK3CA mutations and molecular profiling facilitate therapy selection. Monoclonal antibodies and small molecule inhibitors are some of the targeted medicines examined in the study. It explains how each of these treatments works and supports its findings with data from clinical trials. It also considers potential new medications and addresses persistent problems, such as resistance mechanisms, chances for combining therapies, and cutting-edge patient classification techniques. This study seeks to give healthcare professionals, researchers, and patients a thorough overview of the recent advancements in breast cancer-targeted therapy by drawing on the opinions of top authorities in the area. The coordinated effort aims to create customized, efficient therapies, eventually bolstering the battle against this powerful illness. |
format | Online Article Text |
id | pubmed-10679843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-106798432023-10-28 A Review of the Advancements in Targeted Therapies for Breast Cancer Jallah, John Kessellie Dweh, Tuward J Anjankar, Ashish Palma, Ogiza Cureus Epidemiology/Public Health Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have experienced a profound transformation in treating breast cancer, allowing for individualized strategies that lessen side effects and improve patient outcomes. This thorough analysis gives a rigorous investigation of current developments in breast cancer-targeted treatments. It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. It offers specialized treatment plans catered to each subtype's particular traits. The review also examines how precise genetic abnormalities like BRCA1/2 and PIK3CA mutations and molecular profiling facilitate therapy selection. Monoclonal antibodies and small molecule inhibitors are some of the targeted medicines examined in the study. It explains how each of these treatments works and supports its findings with data from clinical trials. It also considers potential new medications and addresses persistent problems, such as resistance mechanisms, chances for combining therapies, and cutting-edge patient classification techniques. This study seeks to give healthcare professionals, researchers, and patients a thorough overview of the recent advancements in breast cancer-targeted therapy by drawing on the opinions of top authorities in the area. The coordinated effort aims to create customized, efficient therapies, eventually bolstering the battle against this powerful illness. Cureus 2023-10-28 /pmc/articles/PMC10679843/ /pubmed/38022130 http://dx.doi.org/10.7759/cureus.47847 Text en Copyright © 2023, Jallah et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Epidemiology/Public Health Jallah, John Kessellie Dweh, Tuward J Anjankar, Ashish Palma, Ogiza A Review of the Advancements in Targeted Therapies for Breast Cancer |
title | A Review of the Advancements in Targeted Therapies for Breast Cancer |
title_full | A Review of the Advancements in Targeted Therapies for Breast Cancer |
title_fullStr | A Review of the Advancements in Targeted Therapies for Breast Cancer |
title_full_unstemmed | A Review of the Advancements in Targeted Therapies for Breast Cancer |
title_short | A Review of the Advancements in Targeted Therapies for Breast Cancer |
title_sort | review of the advancements in targeted therapies for breast cancer |
topic | Epidemiology/Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679843/ https://www.ncbi.nlm.nih.gov/pubmed/38022130 http://dx.doi.org/10.7759/cureus.47847 |
work_keys_str_mv | AT jallahjohnkessellie areviewoftheadvancementsintargetedtherapiesforbreastcancer AT dwehtuwardj areviewoftheadvancementsintargetedtherapiesforbreastcancer AT anjankarashish areviewoftheadvancementsintargetedtherapiesforbreastcancer AT palmaogiza areviewoftheadvancementsintargetedtherapiesforbreastcancer AT jallahjohnkessellie reviewoftheadvancementsintargetedtherapiesforbreastcancer AT dwehtuwardj reviewoftheadvancementsintargetedtherapiesforbreastcancer AT anjankarashish reviewoftheadvancementsintargetedtherapiesforbreastcancer AT palmaogiza reviewoftheadvancementsintargetedtherapiesforbreastcancer |